Preclinical discovery of novel farnesyltransferase inhibitors for the treatment of Alzheimer's disease and related tauopathies
用于治疗阿尔茨海默病和相关 tau蛋白病的新型法尼基转移酶抑制剂的临床前发现
基本信息
- 批准号:10573238
- 负责人:
- 金额:$ 89.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-15 至 2025-11-30
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAffinityAlzheimer&aposs DiseaseAlzheimer&aposs disease patientAmericanAmyloid beta-ProteinAnimal ModelArtificial IntelligenceAttenuatedBackBehavioralBindingBiological AssayBrainChemicalsClinicClinicalClinical TrialsComputer AssistedCrystallizationCustomDataDementiaDiseaseDisease ProgressionDoseDrug DesignDrug KineticsDrug TargetingElementsFamilyFarnesyl Transferase InhibitorFarnesylation InhibitionGoalsGuanosine Triphosphate PhosphohydrolasesHumanHuman DevelopmentImpaired cognitionKnowledgeLaboratoriesLeadLegal patentLibrariesLonafarnibLongevityLongitudinal StudiesLysosomesMalignant NeoplasmsMediatingMusNeurodegenerative DisordersNeurofibrillary TanglesPathologicPathologyPathway interactionsPatientsPharmaceutical PreparationsPharmacodynamicsPharmacotherapyProcessPropertyProteinsPublic HealthPublishingPumpReportingResearchResearch DesignRiskRoentgen RaysSenile PlaquesSmall Interfering RNAStructureTauopathiesTestingTherapeuticTranslatingValidationWorkaging populationanalogartificial intelligence algorithmartificial intelligence methodcancer therapychemical propertydesigndrug candidatedrug discoveryeffective therapyefficacy studyefficacy testingefflux pumpexperienceextracellularfarnesylationfunctional grouphigh throughput screeningin silicoin vivoinhibitorinnovationlead optimizationmouse modelneural networkneurofibrillary tangle formationneuron lossneuropathologynew therapeutic targetnovelpharmacodynamic modelpharmacologicpre-clinicalpreclinical evaluationpreventprotein degradationproteostasissmall moleculesmall molecule librariestau Proteinstau aggregationtau mutationvirtual
项目摘要
PROJECT SUMMARY
Alzheimer’s disease (AD) is a fatal disease that currently afflicts almost six million Americans. With an
aging population, we risk a public health crisis by 2050, unless effective treatments are identified. Despite
extensive research, there are currently no drugs that slow or alter the course of disease. AD is defined by the
presence of β-amyloid (Aβ) plaques and intraneuronal tau inclusions called neurofibrillary tangles (NFTs) in
the brain. Drug candidates that reduce Aβ plaques have not, yet, been shown to have clinical benefit, and
growing data suggests that it may be more important to target NFTs over Aβ plaques to prevent cognitive
decline. Recently, the macroautophagy-lysosomal pathway of protein degradation has emerged as a
compelling target for reducing pathogenic tau in the brain. Our hypothesis is that increasing the rate of tau
degradation will reduce tau levels and stop, or greatly slow, the rate of tau aggregation. We recently
discovered a novel pathway to accomplish this objective. Inhibiting the farnesylation of Rhes, a GTPase
protein in the Ras family, activates the lysosome and results in the selective degradation of pathological
tau. Confirmation of the therapeutic hypothesis was achieved by administering a farnesyltransferase inhibitor
(FTI) in a mouse model of tauopathy, which reduced tau pathology and attenuated behavioral abnormalities in
the mice.
Known FTIs are not suitable for human development as CNS drugs. Optimized for cancer indications,
they are efficiently pumped out of the brain by efflux proteins. We propose a three-pronged approach to identify
chemical matter that can reach pharmacologically significant and dose-proportional brain levels. For two of the
known inhibitors, L-778,123 and lonafarnib, we will make strategic changes to the structures, eliminating
functional groups that serve as recognition substrates for the efflux pumps. Concurrently, we will initiate a high-
throughput screen of a chemical library with chemical properties consistent with known CNS drugs. As a third
step, we will engage in a multi-million compound artificial intelligence-based virtual screen with AtomWise to
identify novel FTIs. By generating x-ray co-crystal structures of the most promising hits and using computer-
aided drug design, we plan to accelerate the process of hit validation, lead discovery, and optimization to
identify small molecule drug candidates. We will advance inhibitors to an in vivo pharmacodynamic model
and select compounds with linear pharmacokinetic/pharmacodynamic (PK/PD) relationships that can be
advanced into the clinic. Three of the top compounds will be tested for efficacy in a tauopathy animal model
using doses derived from the PK/PD relationship. Short-term studies will identify compounds that reduce all
pathogenic tau species. The most efficacious compound will be moved into long-term dosing studies to
evaluate life-span extension and reduction in NFT formation.
项目摘要
阿尔茨海默病(AD)是一种致命的疾病,目前困扰着近600万美国人。与
人口老龄化,除非找到有效的治疗方法,否则我们到2050年将面临公共卫生危机。尽管
经过广泛的研究,目前还没有药物可以减缓或改变疾病的进程。AD的定义是
β-淀粉样蛋白(Aβ)斑块和称为神经元缠结(NFT)的神经元内tau包涵体的存在,
大脑减少Aβ斑块的候选药物尚未显示出临床益处,
越来越多的数据表明,与Aβ斑块相比,靶向NFT可能更重要,
下降最近,蛋白质降解的大自噬-溶酶体途径已经成为一种新的途径。
减少大脑中致病性tau蛋白的引人注目的目标。我们的假设是增加tau蛋白的表达率
降解将降低tau水平并停止或大大减缓tau聚集的速率。我们最近
发现了一种新的途径来实现这一目标。抑制Rhes的法尼基化,
Ras家族中的一种蛋白质,激活溶酶体并导致病理性细胞因子的选择性降解。
τ的通过给予法尼基转移酶抑制剂证实了治疗假设
(FTI)在tau蛋白病的小鼠模型中,其减少了tau蛋白病并减弱了行为异常,
老鼠
已知的FTI不适合作为CNS药物用于人类开发。针对癌症适应症进行优化,
它们通过外排蛋白被有效地泵出大脑。我们提出了一个三管齐下的方法来确定
化学物质,可以达到显著和剂量成比例的大脑水平。其中两
已知的抑制剂,L-778,123和洛那法尼,我们将对结构进行战略性改变,消除
作为外排泵识别底物的官能团。同时,我们将启动一个高-
通过筛选具有与已知CNS药物一致的化学性质的化学文库。作为第三
下一步,我们将使用AtomWise进行数百万个基于复合人工智能的虚拟屏幕,
识别新的FTI。通过生成最有希望的命中的X射线共晶结构,并使用计算机-
辅助药物设计,我们计划加快命中验证,铅发现和优化的过程,
鉴定小分子候选药物。我们将推进抑制剂的体内药效学模型
并选择具有线性药代动力学/药效学(PK/PD)关系的化合物,
走进诊所。将在tau蛋白病动物模型中测试三种顶级化合物的功效
使用源自PK/PD关系的剂量。短期研究将确定化合物,
致病性tau种类。最有效的化合物将进入长期给药研究,
评估寿命延长和NFT形成的减少。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Steven H Olson其他文献
Steven H Olson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Steven H Olson', 18)}}的其他基金
Preclinical discovery of novel farnesyltransferase inhibitors for the treatment of Alzheimer's disease and related tauopathies
用于治疗阿尔茨海默病和相关 tau蛋白病的新型法尼基转移酶抑制剂的临床前发现
- 批准号:
10367882 - 财政年份:2022
- 资助金额:
$ 89.46万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 89.46万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 89.46万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 89.46万 - 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 89.46万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 89.46万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 89.46万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 89.46万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 89.46万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 89.46万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 89.46万 - 项目类别:
Continuing Grant